Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
NCT03524092Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2018
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 34
01
Overview
A Phase 3 trial of mirikizumab in ulcerative colitis (UC), sponsored by Eli Lilly and Company. Started Oct 2018; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03524092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03524092.